vx984
- Product Name
- vx984
- CAS No.
- 1476074-39-1
- Chemical Name
- vx984
- Synonyms
- vx-984;vx984;VX984,VX 984;VX-984 (M9831);M9831 free base;VX-984, 10 mM in DMSO;VX-984 (Synonyms: M9831);(S)-N-Methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl-4',6'-d2)amino)propan-2-yl)quinoline-4-carboxamide
- CBNumber
- CB83165816
- Molecular Formula
- C23H23N7O
- Formula Weight
- 413.49
- MOL File
- 1476074-39-1.mol
vx984 Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : 8.33 mg/mL (20.05 mM)
- form
- Solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- CS-0017028
- Product name
- VX-984
- Purity
- 99.36%
- Packaging
- 5mg
- Price
- $550
- Updated
- 2021/12/16
- Product number
- CS-0017028
- Product name
- VX-984
- Purity
- 99.36%
- Packaging
- 10mg
- Price
- $950
- Updated
- 2021/12/16
- Product number
- CS-0017028
- Product name
- VX-984
- Purity
- 99.36%
- Packaging
- 50mg
- Price
- $3950
- Updated
- 2021/12/16
vx984 Chemical Properties,Usage,Production
Uses
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium[1][2][3].
in vivo
VX-984 (0-100 mg/kg, Oral gavage, daily) inhibits radiation-induced DNA-PKcs phosphorylation in orthotopic brain tumor xenografts[1].
VX-984 (0-50 mg/kg, Oral gavage, twice a day for 2 days) enhances the radiosensitivity of brain tumor xenografts[1].
| Animal Model: | Athymic female nude mice (6-8 weeks old, 7-8 mice/group, U251 intracerebral xenografts)[1] |
| Dosage: | 0, 50, and 100 mg/kg |
| Administration: | Oral gavage, daily, 1 or 4 hours before irradiation (10 Gy) |
| Result: | Reduced the levels DNA-PKcs phosphorylation after irradiation. |
| Animal Model: | Athymic female nude mice (6-8 weeks old, 7 mice/group, U251 intracerebral xenografts)[1] |
| Dosage: | 0, 50 mg/kg |
| Administration: | Oral gavage, twice a day, 30 minutes before and 4 hours following local irradiation of the tumor (3 Gy) for 3 consecutive days (3×3 Gy) |
| Result: | VX-984 treatment of U251 tumors alone had no significant effect on overall survival as compared with vehicle; radiation alone resulted in an increase in survival. VX-984 and radiation combination protocol increased tumor radiosensitivity, and significantly increased the survival of mice compared with radiation alone. |
References
[1] Timme CR, et al. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts. Mol Cancer Ther. 2018 Jun;17(6):1207-1216. DOI:10.1158/1535-7163.MCT-17-1267
[2] Khan AJ, et al. VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget. 2018 May 25;9(40):25833-25841. DOI:10.18632/oncotarget.25383
[3] Diane Boucher, et al. Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. Cancer Res (2016) 76 (14_Supplement): 3716.
[4] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
vx984 Preparation Products And Raw materials
Raw materials
Preparation Products
vx984 Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@astatechinc.com
- Country
- United States
- ProdList
- 6371
- Advantage
- 58